Navigation Links
OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific
Date:3/16/2009

FT. LAUDERDALE, Fla. and HONG KONG, March 16 /PRNewswire/ -- OrbusNeich Medical, Inc. ("Orbus" or the "Company"), a designer, developer, manufacturer and marketer of innovative medical devices for the treatment of vascular diseases, today announced that it has filed a lawsuit against Boston Scientific Corporation ("BSC"). The lawsuit, filed in the United States District Court for the Eastern District of Virginia, asserts claims against BSC for patent infringement, breach of contract and for misappropriation of trade secrets. The suit seeks unspecified monetary damages and injunctive relief in connection with its claims.

Orbus is the owner by assignment of all right, title, and interest in U.S. Patent No. 7,329,277 entitled "Stent Having Helical Elements" and U.S. Patent No. 6,821,292 entitled "Crimpable Intraluminal Endoprosthesis Having Helical Elements." In its complaint Orbus alleges, among other things, that BSC has infringed these two Orbus patents relating to its proprietary luminal stent technology. Specifically the complaint alleges:

  • In July of 2000, the Company entered into a Confidential Disclosure Agreement (the "CDA") with BSC in advance of discussions related to a potential business relationship;
  • In connection with these discussions, Orbus provided BSC with a variety of proprietary stent samples and design details, including improved designs present in Orbus' patent application filed in December of 2000, which BSC tested, disassembled and destroyed;
  • Orbus filed provisional patents on certain elements of its design on December 11, 2000 and February 9, 2001. The final associated patents were lawfully issued on February 12, 2008 and November 23, 2004, respectively;
  • BSC filed a patent application with new stent design drawings that were not included in any of the provisional applications over which this new application claimed priority;
  • After BSC commercialized the Liberte stent, Orbus became aware of the theft of its designs by BSC; and
  • BSC has been manufacturing and selling its line of Liberte stent products without consideration to Orbus, the original designer of major aspects of the Liberte product architecture, itself.

"OrbusNeich has made significant investments of both funds and resources to develop this innovative technology that is a considerable improvement upon existing cardiovascular devices," said Al Novak, President and Chief Executive Officer. "The protection of these technologies is of the utmost importance to OrbusNeich, and the many talented people who worked to develop them. OrbusNeich has an obligation to its investors, employees and its physician customers and their patients to protect that property from those who seek to infringe upon its rights. We do not anticipate that this process will have an impact on our employees, customers or vendors."

Additional information about background, products, associated patents and the charges raised, please view the Company's Complaint as submitted to the United States District Court for the Eastern District of Virginia. Copies of the Complaint can be obtained through the Court's electronic filing system at www.vaeb.uscourts.gov.

About OrbusNeich

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Products in the company's product portfolio are stents, balloons and guiding catheters marketed under the names of Genous(TM) Bio-engineered R stent(TM), Blazer(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, FL; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit www.orbusneich.com.

    Media Contacts:

    Dan Katcher / Ed Trissel
    Joele Frank, Wilkinson Brimmer Katcher
    +1 212-355-4449 (office)
    dkatcher@joelefrank.com
    etrissel@joelefrank.com


'/>"/>
SOURCE OrbusNeich Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. OrbusNeich Receives CE Mark Approval for Scoreflex(TM) Coronary Dilatation Catheter
2. OrbusNeich Receives Approval to Market Genous(TM) Bio-engineered R stent(TM) in Taiwan
3. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
4. OrbusNeich Receives CE Mark Approval for Sapphire(TM) 1.25MM PTCA Dilatation Catheter
5. 5,000 Patients Treated With OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Now Enrolled in Real-Life Use Global Registry
6. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
7. Why Blood and Bone Marrow Donors Are So Important: Extreme Makeover: Home Edition Profiles Blood Drive Honoree Lizzie Bell
8. Santa Monica Media Corporation Files Extension Proxy With SEC to Complete Transaction
9. Unemployment Rises, Profiles International Reveals Whos Hiring
10. Cordex Pharma Files ATPace Formulation Patent
11. United States Files Suit Against Missouri-Based Pharmaceutical to Block Manufacturing and Shipping of Unapproved Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , ... March 29, 2017 , ... AvePoint , ... North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East ... by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual ... the Diabetes Risk Test to find out if they are at risk for developing ... light up the evening sky by programming the LAX pylons the color red. Downtown’s ...
(Date:3/28/2017)... CARTERSVILLE, Georgia (PRWEB) , ... March 28, 2017 ... ... analyst to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, ... been a leader in the real estate valuation industry for more than 40 ...
(Date:3/28/2017)... ... , ... The Thyroid Secret is a specialized 9-part documentary ... was recently launched on March 1, and Dr. Wentz discussed varied benefits and ... Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After being ...
(Date:3/28/2017)... ... March 28, 2017 , ... Medforce Technologies, Inc., ... to announce it has joined the National Association for Home Care and Hospice ... ill, disabled, and dying Americans of all ages and the caregiver who provide ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") ... financial results for the year ended December 31, ... 2017. The results are being released later than ... statements will include the operations and balances of ... 2016.  This release and filing date meets TSX ...
(Date:3/28/2017)... March 28, 2017 The global emerging cancer ... of 13.45% from 2016 to 2023 and reach a ... Cancer is a chronic disease and is affecting ... cancer diagnostics market. This report is focused on emerging ... market growth is propelled due to factors such as: ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
Breaking Medicine Technology: